Strengthening Immunisation in the Eastern Mediterranean: WHO Launches Regional Framework

By Melike Belenli Gümüş

October 31, 2024

World Health Organization (WHO) Regional Office for the Eastern Mediterranean announced the launch of the regional framework to strengthen immunisation. This framework was inaugurated on October 15, 2024, in Doha, Qatar, as part of a global initiative aimed at enhancing immunisation within primary health care systems.

Current Challenges in Vaccine Access

One in four children in the region lacks access to essential vaccines like pneumococcal and rotavirus. This issue is particularly prevalent in middle-income countries. Furthermore, a staggering 90% of adolescent girls in the region do not receive the HPV vaccine. Of these, 63% live in Gavi-eligible countries. These statistics highlight the urgent need for improved vaccine access across the region.

Expanding Immunisation Coverage

Expanding immunisation coverage throughout the life course is vital. New vaccines targeting high-risk groups, such as health care workers and the elderly, are essential. Establishing vaccine delivery platforms beyond infancy, in settings like schools and workplaces, presents a significant challenge for national immunisation programmes. Addressing these challenges is crucial for the success of Immunization Agenda 2030 (IA2030).

Launch of the Regional Framework

To adapt IA2030 to the needs of the Eastern Mediterranean Region, a strategic framework has been developed. The launch of the regional framework to strengthen immunisation represents a significant step towards facilitating access to essential vaccines in the region. The initiative acknowledges that vaccines are a critical tool, saving over 4 million lives annually. This framework is the result of extensive consultations with national immunisation programmes, the Regional Immunization Technical Advisory Group, and key stakeholders. It reflects the priorities of Member States and includes a comprehensive monitoring and evaluation system. This system will track progress towards the ambitious goals set forth in IA2030.

Objectives

The primary aim of the framework is to improve access to vital vaccines, which remains a pressing concern throughout the region. By addressing disparities in vaccine coverage, especially in conflict-affected areas, the framework seeks to make a meaningful impact on public health.

Context

This initiative’s launch is particularly timely due to the ongoing efforts to tackle health challenges in the Eastern Mediterranean Region. Significant disparities in vaccine accessibility have been noted, making this framework’s objectives even more crucial for the overall health of the population.

Event Details

The launch of the regional framework to strengthen immunisation occurred during the 71st session of the WHO Regional Committee for the Eastern Mediterranean (RC71). The theme of the session was “health beyond borders: action, access, equity,” emphasising the need for collaborative health strategies.

Key figures who inaugurated the event included WHO Director-General Dr. Tedros Adhanom Ghebreyesus, WHO Regional Director for the Eastern Mediterranean Dr. Hanan Balkhy, and H.E. the Minister of Public Health of Qatar Dr. Hanan Al-Kuwari. Their participation highlights the commitment to advancing immunisation efforts in the region.

Political Commitment and Immunisation Awareness

Fostering political commitment and raising awareness about the importance of immunisation is essential. This is crucial for sustaining health achievements and preparing for future pandemics. In fragile, conflict-affected, and vulnerable countries, health care systems are often severely disrupted. This disruption severely impacts primary health care and immunisation services. The COVID-19 pandemic intensified these challenges, leading to growing immunity gaps.

Overall Goal

In conclusion, the framework aims to strengthen immunisation efforts, ensuring equitable access to vaccines and essential health services for all people in the region. With the support of Member States, the framework will strengthen immunisation services across the region. This initiative aligns with the broader goal of enabling all individuals in the Eastern Mediterranean to lead the healthiest lives possible. This will save lives and improve health outcomes for millions.

Reference url

Recent Posts

NICE Endorses Rozanolixizumab for Myasthenia Gravis Treatment

By João L. Carapinha

May 1, 2026

Rozanolixizumab myasthenia gravis treatment has been recommended by the National Institute for Health and Care Excellence (NICE) as an add-on to standard care for adults with generalised myasthenia gravis (gMG) who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosi...
Accelerating Biotechnology Patient Access in Europe Through Strategic Policy Reforms
The biotechnology patient access gap in Europe remains a critical challenge despite the continent’s scientific excellence. The EU Biotech Act offers a strategic opportunity to accelerate the delivery of advanced therapies — such as radioligand, cell and gene, and RNA-based treatments — from disco...
Insulin Substitution Portugal: Implications of Novo Nordisk’s Discontinuation
INFARMED has informed healthcare professionals about the upcoming discontinuation of several Novo Nordisk insulin products in Portugal and to provide clear guidance on insulin substitution Portugal. On 30 April 2026, INFARMED issued Circular 045/CD/100.20.200 announcing that Novo Nordisk Portu...